Lung adenocarcinoma and antiphospholipid antibodies

Meis, Ernesto de; Monteiro, Robson Q.; Levy, Roger A.

doi:10.1016/j.autrev.2009.01.010

Cited by 11 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main reasons for exclusion included: no correlation of serologic results with thrombosis; measurement of only IgG or only IgM antibodies; no discrimination between IgG and IgM antibodies; presentation of combined antibody results; only LA/non‐criteria antibodies being measured; and the inclusion of overlapping patient populations. Thus, 177 studies were included in this systematic review . Those studies were grouped according to their analysis method: those containing ORs for thrombosis or allowing their calculation, and those for which, owing to a lack of information, only the percentage of positive patients in the thrombotic population can be shown.…”

Section: Resultsmentioning

confidence: 99%

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

Kelchtermans

Pelkmans

Laat

et al. 2016

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

The clinical value of IgM antibodies in thrombotic antiphospholipid syndrome (APS) is debated. By review of literature, we reconsidered the clinical value of IgM antibodies in thrombotic APS. More significant correlations with thrombosis were found for the IgG compared to IgM isotype. Unavailability of paired IgG/IgM results hampers evaluating the added value of IgM positivity. https://www.youtube.com/watch?v=XTMLAqOkJ7w Summary BackgroundDespite the update of the classification criteria for the antiphospholipid syndrome (APS), difficulties persist in the identification of patients at risk for thrombosis. Current guidelines include assays detecting IgG/IgM anti‐β2‐glycoprotein I and anti‐cardiolipin antibodies, although the relevance of IgM antibodies has been debated. ObjectivesThrough a review of the literature from 2001 to 2014, we aimed to formally establish the thrombotic risk stratification potential of IgM as compared with IgG anti‐phospholipid antibodies (aPLs). Patients/methodsOne thousand two hundred and twenty‐eight articles were selected by a computer‐assisted search of the literature. Of the 177 studies that met our inclusion criteria, the clinical value of IgG/IgM aPLs was established through analysis of odds ratios for thrombosis or percentage of positives in the thrombotic population. Results/conclusionsWe clearly found more significant correlations with thrombosis for the IgG than for the IgM isotype. Nonetheless, in a minority of studies, significant associations with thrombosis were found for IgM but not IgG antibodies. The unavailability of paired results of IgG and IgM for each separate patient hampers evaluation of the added value of isolated IgM positivity. To fully take advantage of results obtained by future studies, we strongly encourage scientists to provide all studied information per patient. We planned a large multicenter study to investigate clinical associations of isolated/combined positivity for criteria/non‐criteria aPLs. Importantly, because of the presence of non‐pathogenic aPLs, quantitative assays are characterized by a high false‐positivity rate. Optimization of functional assays, such as thrombin generation measuring the whole scheme of coagulation, may help to reduce APS‐related morbidity and mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

Kelchtermans

Pelkmans

Laat

et al. 2016

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Another possibility is that additional thrombogenic factors may have a strong influence on lung adenocarcinoma-related thrombosis. In this regard, we recently observed that positivity for antiphospholipid antibodies is a strong risk factor for thrombosis outcome in lung adenocarcinoma (22). Finally, since post-mortem analyses have not been routinely performed in our Institution, occult pulmonary embolism cannot be excluded in patients with increased TF expression.…”

Section: Discussionmentioning

confidence: 99%

Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma

Meis

Azambuja

Ayres-Silva

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…APLAs also contribute to the predictive value of the International Prognostic Index (IPI) [ 41 ]. For example, in lung adenocarcinoma patients, LA activity correlates with lower survival rates [ 42 ]. Therefore some authors suggest using laboratory tests detecting APLAs as a diagnostic tool, which may predict oncological outcomes [ 39 ].…”

Section: Methodsmentioning

confidence: 99%

Positive antiphospholipid antibodies: observation or treatment?

Grygiel-Górniak

Mazurkiewicz

2023

J Thromb Thrombolysis

View full text Add to dashboard Cite

Antiphospholipid antibodies (APLAs) are primarily directed toward phospholipid-binding proteins and are responsible for thrombotic events. APLAs include anti-β2Glycoprotein I (anti-β2GPI), anticardiolipin (anti-CL) antibodies, and lupus anticoagulant. These antibodies are typical markers of antiphospholipid syndrome (APS) and are a part of its diagnostic criteria. Many data underline the presence of APLAs in other rheumatic diseases (e.g., systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, rheumatoid arthritis and Behçet’s disease). However, they are also detected in patients with cancer, infection, and neurological disorders. Furthermore, healthy individuals may be carriers of APLAs. Chronic asymptomatic APLAs presence is most common in the elderly and subjects with chronic diseases (including malignancies). Specific kinds of APLAs are considered markers of oncological progression. These antibodies occur in 6% of pregnant women (without diagnosed APS) and are related to many pregnancy complications. Of worth, various types of APLAs are reported to have different prothrombotic properties. The risk of thrombotic events in APLA-positive but clinically naïve patients raises many questions in clinical practice. This manuscript analyses various clinical situations and consequences of the APLAs’ presence, particularly in patients without diagnosed APS. The prevalence, etiology, molecular background, and prothrombotic properties of numerous APLAs are broadly discussed. The new management approach in different clinical conditions and organ complications is present in the context of recent recommendations. Discussed data underlines that adequate and timely introduced thromboprophylaxis can decrease the risk of thrombus formation and prevent increased morbidity.

show abstract

Lung adenocarcinoma and antiphospholipid antibodies

Cited by 11 publications

References 32 publications

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma

Positive antiphospholipid antibodies: observation or treatment?

Contact Info

Product

Resources

About